Literature DB >> 8453956

Comparative effects of felodipine, nitrendipine and nifedipine in healthy subjects: concentration-effect relationships of racemic drugs and enantiomers.

P A Soons1, A F Cohen, D D Breimer.   

Abstract

The effects of racemic (rac) felodipine, rac-nitrendipine and nifedipine (all 20 mg solution p.o.) on non-invasively measured blood pressure and heart rate were investigated in a randomised, double-blind, cross-over study in 12 normotensive, young, healthy males. Compared to baseline values, heart rate increased more after rac-felodipine treatment (+47% at maximum) than rac-nitrendipine (+40%) and nifedipine (+38%); only small and variable changes in blood pressure were observed with any of the drugs. The baseline-corrected area under the heart rate-time curve up to 4 h after the administration of rac-felodipine was 197% and 180% larger than after nifedipine and rac-nitrendipine treatment, respectively. The effects on heart rate could be fitted individually to a sigmoidal Emax-model without hysteresis for all drugs under investigation. The relative potencies of the unbound drugs for their indirect effects on heart rate were 1:7:43 for nifedipine, rac-nitrendipine and rac-felodipine, respectively. The active (S)-enantiomers of felodipine and nitrendipine appeared to be 9- and 60-times as potent as nifedipine in this respect, assuming no (inter)activity of the (R)-enantiomers. Individual and mean changes in blood pressure were small, they were not related to plasma concentrations, and did not differ between treatments.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453956     DOI: 10.1007/bf00315467

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  37 in total

Review 1.  Ca2+ channel ligands: structure-function relationships of the 1,4-dihydropyridines.

Authors:  D J Triggle; D A Langs; R A Janis
Journal:  Med Res Rev       Date:  1989 Apr-Jun       Impact factor: 12.944

Review 2.  Historical overview. The calcium channel of the heart.

Authors:  A Fleckenstein
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

3.  Pharmacokinetics and pharmacodynamics of nifedipine in patients at steady state.

Authors:  L M Gutierrez; L J Lesko; R Whipps; N Carliner; M Fisher
Journal:  J Clin Pharmacol       Date:  1986 Nov-Dec       Impact factor: 3.126

4.  Plasma concentration-effect relationships of intravenous and extended-release oral felodipine in hypertensive patients.

Authors:  E Blychert; T Hedner; C Dahlöf; D Elmfeldt
Journal:  J Cardiovasc Pharmacol       Date:  1990-03       Impact factor: 3.105

5.  Pharmacokinetics of felodipine in patients with impaired renal function.

Authors:  B Edgar; C G Regårdh; P O Attman; M Aurell; H Herlitz; G Johnsson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

6.  Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses.

Authors:  B Edgar; C G Regårdh; P Lundborg; S Romare; G Nyberg; O Rönn
Journal:  Biopharm Drug Dispos       Date:  1987 May-Jun       Impact factor: 1.627

7.  Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans.

Authors:  C H Kleinbloesem; P van Brummelen; M Danhof; H Faber; J Urquhart; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

8.  Dihydropyridine receptor in rat brain labeled with [3H]nimodipine.

Authors:  P Bellemann; A Schade; R Towart
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

Review 9.  Calcium antagonism and calcium entry blockade.

Authors:  T Godfraind; R Miller; M Wibo
Journal:  Pharmacol Rev       Date:  1986-12       Impact factor: 25.468

10.  Stereoselective inhibition of thromboxane-induced coronary vasoconstriction by 1,4-dihydropyridine calcium channel antagonists.

Authors:  M Eltze; R Boer; K H Sanders; H Boss; W R Ulrich; D Flockerzi
Journal:  Chirality       Date:  1990       Impact factor: 2.437

View more
  5 in total

1.  Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers.

Authors:  H Ericsson; C Fakt; A Jolin-Mellgård; M Nordlander; L Sohtell; M Sunzel; C G Regårdh
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

2.  Determination of (+)- and (-)-nicardipine concentrations in human serum and their correlation with the antihypertensive effect after oral administration of racemic nicardipine.

Authors:  T Iwaoka; N Inotsume; J Inoue; S Naomi; Y Okamoto; S Higuchi; M Nakano; T Umeda
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Authors:  P A Soons; C Grib; D D Breimer; W Kirch
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

4.  1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.

Authors:  Mauro Cataldi; Fiorentina Bruno
Journal:  Transl Med UniSa       Date:  2012-10-11

Review 5.  Enantioselectivity in Drug Pharmacokinetics and Toxicity: Pharmacological Relevance and Analytical Methods.

Authors:  Maria Miguel Coelho; Carla Fernandes; Fernando Remião; Maria Elizabeth Tiritan
Journal:  Molecules       Date:  2021-05-23       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.